KA
Live price temporarily unavailable.
Price history
KALA BIO (KALA) is a Health Care company. Latest news and coverage below.
IPO: July 20, 2017 · $15.00 offering · NASDAQ · View IPO details →
KALA BIO revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | — | $6.07M | $6.36M | $11.2M | $3.89M | $0 | $0 | $0 |
| Growth (year over year) | −100.0% | — | — | — | +4.7% | +76.7% | −65.4% | −100.0% | — | — |
| Operating income | −$32.7M | −$39.9M | −$64.7M | −$88.2M | −$96.2M | −$130.2M | −$81.7M | −$39.7M | −$41.0M | −$39.2M |
| Operating margin | — | — | — | −1452.5% | −1512.6% | −1158.8% | −2099.3% | — | — | — |
| Net income | −$33.2M | −$42.2M | −$66.7M | −$94.3M | −$104.3M | −$142.6M | −$44.8M | −$42.2M | −$38.5M | −$27.0M |
| Net margin | — | — | — | −1553.3% | −1639.8% | −1268.7% | −1151.6% | — | — | — |
| EPS (diluted) | −$175437500.00 | −$23187500.00 | −$15562500.00 | −$17250000.00 | −$4975.00 | −$5416.00 | −$1474.00 | −$867.50 | −$507.50 | −$165.50 |
| Balance sheet | ||||||||||
| Cash and equivalents | $45.5M | $114.7M | $183.1M | $85.4M | $77.3M | $92.1M | $70.5M | $50.9M | $51.2M | $7.56M |
| Total assets | $46.3M | $116.5M | $221.0M | $154.3M | $221.6M | $139.4M | $86.8M | $55.9M | $55.5M | $9.49M |
| Total liabilities | $15.7M | $26.9M | $116.0M | $124.6M | $121.6M | $122.6M | $67.8M | $48.4M | $43.2M | $2.49M |
| Long-term debt | $9.10M | $12.0M | $70.2M | $71.2M | $72.2M | $78.9M | $37.9M | $34.2M | $20.1M | — |
| Shareholders' equity | −$87.8M | $89.7M | $105.0M | $29.7M | $100.0M | $16.8M | $19.0M | $7.50M | $12.3M | $7.00M |
| Cash flow | ||||||||||
| Operating cash flow | −$27.3M | −$34.1M | −$54.1M | −$92.7M | −$90.7M | −$108.2M | −$78.9M | −$27.9M | −$29.4M | −$32.0M |
| Capital expenditure | $153.0K | $480.0K | $1.58M | $1.33M | — | — | — | — | — | — |
| Free cash flow | −$27.5M | −$34.6M | −$55.7M | −$94.1M | — | — | — | — | — | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$9.99M | −$9.46M | −$10.7M | −$11.0M | −$7.24M | −$10.2M | −$1.80M | −$1.72M |
| Net income | −$8.95M | −$8.18M | −$8.95M | −$11.2M | −$7.56M | $686.0K | −$1.62M | −$1.58M |
| EPS (diluted) | −$96.50 | −$43.00 | −$70.49 | −$85.64 | −$53.50 | $44.13 | −$0.14 | −$21.32 |
| Balance sheet | ||||||||
| Cash and equivalents | $49.2M | $51.2M | $42.2M | $31.9M | $21.1M | $7.56M | $1.76M | $229.0K |
| Total assets | $54.1M | $55.5M | $48.3M | $36.1M | $25.0M | $9.49M | $12.3M | $10.6M |
| Total liabilities | $47.2M | $43.2M | $42.5M | $39.3M | $33.7M | $2.49M | $1.56M | $1.54M |
| Long-term debt | $17.2M | $20.1M | $15.1M | $18.8M | $26.9M | — | — | — |
| Shareholders' equity | $6.86M | $12.3M | $5.71M | −$3.21M | −$8.66M | $7.00M | $10.8M | $9.04M |
| Cash flow | ||||||||
| Operating cash flow | −$4.72M | −$4.60M | −$8.82M | −$16.6M | −$10.9M | $4.27M | −$2.90M | −$1.53M |
From KALA BIO's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About KALA BIO
- Headquarters
- Arlington, Massachusetts From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with KALA
- JAZZ Jazz Pharmaceuticals
- JBIO Jade Biosciences Inc
- JUNS Jupiter Neurosciences
- JYNT Joint Corp
- KALV Kalvista Pharmaceuticals Inc
- KARD Kardigan, Inc.
- KIDS Orthopediatrics Corp
- KLRA Kailera Therapeutics